Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

8 Jul 2011
New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

8 Jul 2011
Study confirms benefits of low-dose spiral CT scans for lung cancer detection

Study confirms benefits of low-dose spiral CT scans for lung cancer detection

30 Jun 2011
Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

29 Jun 2011
Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

28 Jun 2011
New model of health care delivery relies on active participation of patients and caregivers

New model of health care delivery relies on active participation of patients and caregivers

24 Jun 2011
EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

From Baxter International Inc. 24 Jun 2011
Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

18 Jun 2011
Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

17 Jun 2011
REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

17 Jun 2011
New Australian drug shows positive response in patients with multiple myeloma blood cancer

New Australian drug shows positive response in patients with multiple myeloma blood cancer

16 Jun 2011
Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

16 Jun 2011
Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

13 Jun 2011
Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

8 Jun 2011
Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

6 Jun 2011
ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

6 Jun 2011
EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

4 Jun 2011
ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

3 Jun 2011
VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

3 Jun 2011
XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

2 Jun 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback